The U Food and Drug Administration (FDA) has completed its review of Moderna’s investigational new drug (IND) application for Covid-19 vaccine candidate, mRNA-1273,  authorising the company to conduct a Phase II study.

The protocol for Phase III study of mRNA-1273 has also been finalised. While the Phase II clinical trial is set to begin soon, the Phase III study will be conducted later this year.